• Azzour D Hazzan, Hitesh H Shah, Susana Hong, Vipulbhai Sakhiya, Rimda Wanchoo, and Steven Fishbane.
• Division of Kidney Diseases and Hypertension, Department of Medicine, North Shore University Hospital, Long Island Jewish Medical Center Hofstra, North Shore-LlJ School of Medicine, Great Neck, New York, USA.
• Kidney Int. 2014 Jul 1; 86 (1): 34-9.

AbstractTreatment of anemia remains an important component in the care of patients with nondialysis chronic kidney disease (CKD) and end-stage renal disease (ESRD). Erythropoietin-stimulating agents (ESAs) remains a key anemia treatment strategy in this patient population. However, anemia management in this group can become more complicated by prior or current history of malignancy. There has been a great deal of work both scientifically and in clinical trials in oncology that have revealed certain concerns and risks of ESA use in patients with cancer. In this review, we will bring together knowledge from nephrology and oncology literature to help nephrologists understand the implications for ESA treatment when CKD/ESRD is complicated by cancer. We also suggest an approach to the management of anemia in this patient group with active or previous malignancy.

27 keywords...

hide…